The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Most employers are expecting to hire this year, according to BioSpace data and Recruitment Manager Greg Clouse, who noted ...

"AI is going to help kick in some of that load that the scientists and researchers do at the front end to quickly get a diagnosis," said Deema Tarazi.

A survey of the nation's oncologists showed that professional burnout has reached a new high (59% vs 45% in 2013), and fewer ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

An FDA safety announcement regarding labeling changes for the commonly used oncology drugs capecitabine and 5-fluorouracil highlights a risk of dihydropyrimidine dehydrogenase deficiency, which can ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Barrington analyst Gary Prestopino maintained a Buy rating on DHI Group (DHX – Research Report) today and set a price target of $7.00. The ...

In a report released today, Eric Martinuzzi from Lake Street maintained a Buy rating on DHI Group (DHX – Research Report), with a price target ...

BioSpace reported that Eli Lilly faces fierce competition from Novo Nordisk (NYSE:NVO)'s Wegovy and Ozempic, which has led to lower-than-expected demand for Eli Lilly's weight loss and diabetes ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.